These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 21473706)

  • 1. Pharmacotherapy of overactive bladder: epidemiology and pathophysiology of overactive bladder.
    Latini JM; Giannantoni A
    Expert Opin Pharmacother; 2011 May; 12(7):1017-27. PubMed ID: 21473706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in the pharmacotherapy of the overactive bladder.
    Sellers DJ; McKay N
    Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current management and future perspectives of overactive bladder (OAB) pharmacotherapy.
    Dobrek Ł; Juszczak K; Wyczółkowski M; Thor PJ
    Acta Pol Pharm; 2011; 68(6):807-21. PubMed ID: 22125944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study.
    Sexton CC; Coyne KS; Thompson C; Bavendam T; Chen CI; Markland A
    J Am Geriatr Soc; 2011 Aug; 59(8):1465-70. PubMed ID: 21718275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ["Pathophysiology and treatment of the overactive bladder"].
    Yokoyama O
    Hinyokika Kiyo; 2005 Sep; 51(9):599-601. PubMed ID: 16229372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder?
    Giarenis I; Mastoroudes H; Srikrishna S; Robinson D; Cardozo L
    BJU Int; 2013 Aug; 112(4):501-7. PubMed ID: 23452071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of prostanoids in the urinary bladder function and a potential use of prostanoid-targeting pharmacological agents in bladder overactivity treatment.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2015; 72(1):13-9. PubMed ID: 25850196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
    Cerruto MA; Asimakopoulos AD; Artibani W; Del Popolo G; La Martina M; Carone R; Finazzi-Agrò E
    Urol Int; 2012; 89(1):1-8. PubMed ID: 22738896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.
    Peyronnet B; Mironska E; Chapple C; Cardozo L; Oelke M; Dmochowski R; Amarenco G; Gamé X; Kirby R; Van Der Aa F; Cornu JN
    Eur Urol; 2019 Jun; 75(6):988-1000. PubMed ID: 30922690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women.
    Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I
    Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of symptoms with urodynamic findings in men with overactive bladder syndrome.
    Al-Zahrani AA; Gajewski JB
    BJU Int; 2012 Dec; 110(11 Pt C):E891-5. PubMed ID: 22928556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology and pharmacotherapy of overactive bladder.
    Yoshida M; Masunaga K; Nagata T; Yono M; Homma Y
    J Pharmacol Sci; 2010; 112(2):128-34. PubMed ID: 20134115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
    Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
    Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
    Haab F
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S2-5. PubMed ID: 25042138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Overactive bladder in female and new strategy].
    Kubota Y; Sasaki S; Kojima Y; Hayase M; Kohri K
    Hinyokika Kiyo; 2007 Jun; 53(6):435-9. PubMed ID: 17628947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic organ prolapse and overactive bladder.
    de Boer TA; Salvatore S; Cardozo L; Chapple C; Kelleher C; van Kerrebroeck P; Kirby MG; Koelbl H; Espuna-Pons M; Milsom I; Tubaro A; Wagg A; Vierhout ME
    Neurourol Urodyn; 2010; 29(1):30-9. PubMed ID: 20025017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.